Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07091149

Digital Cognitive Behavioral Treatment of Insomnia in Youth: An RCT Examining Feasibility, Acceptability, and Efficacy of NiteCAPP Jr

The proposed pilot will examine feasibility, acceptability, and preliminary efficacy of a digital CBT-I tailored for school-aged children.

Recruiting

Interested in participating?

Request Info

Key information

Age range

6 year–12 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of South Florida

Tampa, Florida, 33612, United States

Location status: Recruiting

Location contact

Christina S McCrae, PhD

CONTACT

About this study

This is a pilot study to examine feasibility, acceptability, and preliminary efficacy of a digital CBT-I tailored for school-aged children aged 6-12 with insomnia and their caregiver(s) compared to a waitlist control.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Child inclusion:

  • 6-12 yrs
  • Verbal IQ > 70 (to ensure verbal skills are sufficient to participate in treatment)
  • participation of child's parent or legal guardian living in the same home
  • child diagnosed with insomnia, 5) willing to accept random assignment.

Insomnia:

  • insomnia complaints for 3+ months by child report or caregiver observation that consist of (a) difficulties falling asleep, staying asleep, and/or waking up too early, (b) daytime dysfunction (mood, cognitive, social, occupational) due to insomnia, and (c) Pediatric Insomnia Severity Index score >8

Caregiver inclusion:

  • ability to read and understand English at the 5th grade level
  • willing to accept random assignment.

Exclusion criteria

Child exclusion:

  • child unable to provide informed consent or child unable to provide assent
  • child unwilling to accept random assignment
  • child participation in another randomized research project
  • child unable to complete forms or implement treatment procedures due to cognitive impairment
  • child untreated medical comorbidity including other sleep disorders (e.g., apnea, epilepsy, psychotic disorders, suicidal ideation/intent, [frequent] parasomnias)
  • child psychotropic or other medications that alter sleep with the exceptions of stimulants, sleep medications, and/or melatonin as described in #7 (see Notes below for details)
  • child stimulants, sleep medications (prescribed or OTC), and/or melatonin within the last 1 month (unless stabilized on medication for 3+ months)
  • child participation in non-pharmacological treatment (including CBT) for sleep outside current trial
  • child other conditions adversely affecting trial participation.

Caregiver exclusion criteria:

  • unable to provide informed consent
  • unwilling to accept random assignment
  • caregiver participation in another randomized research project
  • unable to complete forms or implement treatment procedures due to cognitive impairment
  • caregiver participation in non-pharmacological treatment (including CBT) for sleep outside current trial

Treatment and study plan

CBT-I

Behavioral

Cognitive behavioral therapy for insomnia

Primary outcomes

  1. Electronic Sleep Diaries - Child

    Time frame: baseline, within 1 week post treatment, 1 month follow up, 3 month follow up

    Primary: child sleep onset latency (lights-out until sleep onset) and total sleep time. All other sleep diary variables are secondary (e.g., sleep efficiency (total sleep time/time in bed x 100%). Child (with caregiver assistance) and caregiver complete electronic diaries each morning (~5 mins) during each 1-week assessment and throughout treatment.

  2. Actigraphy - Child

    Time frame: baseline, within 1 week post treatment, 1 month follow up, 3 month follow up

    Primary variables: child sleep onset latency and total sleep time. All other actigraphy variables are secondary. Children wear actigraphs (Fitbit Inspire 3, Google), watch-like device, that monitors light and gross motor activity. Data analyzed using 30s epochs. Validated algorithm estimates SOL, TST, WASO, sleep efficiency and other variables provided by diaries. A combination of diary and actigraphy data estimates bed/waketime variability. Children wear devices 24/7 during each 1-week assessment.

  3. Session Completion

    Time frame: within 1 week post-treatment

    Percentage of treatment sessions completed

  4. Treatment Adherence

    Time frame: within 1 week post-treatment

    Percentage of instructions followed as indicated on treatment adherence logs

  5. Internet Intervention Utility Questionnaire (IIUQ)

    Time frame: within 1 week post-treatment

    16-item measure designed to assess usability, likeability, usefulness, understandability, and convenience of an Internet intervention using a 5-point Likert scale, ranging from 0 (not at all) to 4 (very). Two additional open-ended questions ask about the most and least helpful aspects of the program. Scoring range is 0-64.

  6. Treatment Satisfaction Survey

    Time frame: within 1 week post-treatment

    9-item measure designed to provide feedback on the study, including its structure, assessments, scheduling, working with study staff, and the usability of the intervention platforms using a 10-point Likert scale, ranging from 1 (strongly disagree) to 10 (strongly agree) and open-ended questions

  7. Pediatric Insomnia Severity Index

    Time frame: baseline, within 1 week post treatment, 1 month follow up, 3 month follow up

    The Pediatric Insomnia Severity Index is a six-item questionnaire that assesses insomnia symptom severity in children 4-10 years old. Items are rated on a 0-6 point scale based on the child's sleep over the past week. Scoring range is 0-30 with with higher scores indicating greater insomnia severity.

Secondary outcomes

  1. Child Sleep Habits Questionnaire-Abbreviated

    Time frame: baseline, within 1 week post treatment, 1 month follow up, 3 month follow up

    The Child Sleep Habits Questionnaire - Abbreviated consists of 22 questions regarding child sleep behaviors on a 1 point scale (0 = never, 7 = always). Higher scores indicating issues with sleep habits.

  2. Pediatric Symptom Checklist-17

    Time frame: baseline, within 1 week post treatment, 1 month follow up, 3 month follow up

    The Pediatric Symptom Checklist-17 is a 17-item questionnaire that measures attention, internalizing, and externalizing problems on a 0-2 scale. Scores range from 0-34 with higher score indicates a greater level of psychosocial impairment.

  3. Behavior Rating Inventory of Executive Function -2nd Edition (BRIEF-2)

    Time frame: baseline, within 1 week post treatment, 1 month follow up, 3 month follow up

    The Behavior Rating Inventory of Executive Function -2nd Edition (BRIEF-2) is an 86-item caregiver-report measure of day-to-day executive functioning and impairment. T-scores ranging from 30-90 with higher scores indicating greater executive functioning difficulties

  4. Pediatric Daytime Sleepiness Scale

    Time frame: baseline, within 1 week post treatment, 1 month follow up, 3 month follow up

    The Pediatric Daytime Sleepiness Scale is an 8-item questionnaire that measures daytime sleepiness and school-related outcomes on a 5-point scale. Scores range from 0-32 with higher scores indicating greater daytime sleepiness.

  5. Revised Children's Anxiety and Depression Scale-25

    Time frame: baseline, within 1 week post treatment, 1 month follow up, 3 month follow up

    The Revised Children's Anxiety and Depression Scale-25 (caregiver report) is a 25-item scale that measures levels of anxiety and depression on a 4-point scale. Scores range from 0-75 with higher scores indicating more severity in symptoms.

  6. Strengths and Difficulties Questionnaire

    Time frame: baseline, within 1 week post treatment, 1 month follow up, 3 month follow up

    The Strengths and Difficulties Questionnaire is a 25-item questionnaire that measures five scales (emotional symptoms, conduct problems, hyperactivity/inattention, peer relationship problems, and prosocial behavior) on a 4-point scale. Scores range from 0-40 with higher scores indicating greater difficulties across emotional, behavioral, and peer domains.

  7. Heart rate variability - Child

    Time frame: baseline, within 1 week post treatment, 1 month follow up, 3 month follow up

    HRV will be assessed using Holter Monitoring during an established stress reactivity protocol. Participants will be seated at rest and undergo Holter Monitoring procedures: 1) 5 min baseline, 2) 30 secs vibrotactile stimuli (Conair WM200X, Stamford, CT) at 80 Hz oscillations applied to left hand, 3) 3 min recovery, 4) 30 secs vibrotactile stimuli applied to right hand, 5) 3 min recovery, 6) cold pressor stimulation to right hand (place hand to bottom of bowl of ice water calibrated to 4° C), 7) 3 min recovery, 8) cold pressor stimulation to left hand. Time and spectral analysis of short-term HRV during baseline, vibration and cold pressor stimuli will be conducted in BioPAC software. Time (reflects beat-to-beat variability-RMSDNN, pNN50) and frequency [reflects underlying HR rhythms-High (0.15-0.4 Hz), low (0.04-0.15 Hz), very low (below 0.04 Hz), LF/HF ratio] domains will be examined.

  8. Peds Quality of Life

    Time frame: baseline, within 1 week post treatment, 1 month follow up, 3 month follow up

    PedsQL is a 23-item scale measuring children's QOL. It has excellent internal consistency, clinical validity, and factor-analytic support. Caregiver forms will be completed. Scores ranges from 0-100 with higher scores indicating better quality of life.

  9. Heart rate variability - Caregiver

    Time frame: baseline, within 1 week post treatment, 1 month follow up, 3 month follow up

    HRV will be assessed using Holter Monitoring during an established stress reactivity protocol. Participants will be seated at rest and undergo Holter Monitoring procedures: 1) 5 min baseline, 2) 30 secs vibrotactile stimuli (Conair WM200X, Stamford, CT) at 80 Hz oscillations applied to left hand, 3) 3 min recovery, 4) 30 secs vibrotactile stimuli applied to right hand, 5) 3 min recovery, 6) cold pressor stimulation to right hand (place hand to bottom of bowl of ice water calibrated to 4° C), 7) 3 min recovery, 8) cold pressor stimulation to left hand. Time and spectral analysis of short-term HRV during baseline, vibration and cold pressor stimuli will be conducted in BioPAC software. Time (reflects beat-to-beat variability-RMSDNN, pNN50) and frequency [reflects underlying HR rhythms-High (0.15-0.4 Hz), low (0.04-0.15 Hz), very low (below 0.04 Hz), LF/HF ratio] domains will be examined.

  10. Actigraphy - Caregiver

    Time frame: baseline, within 1 week post treatment, 1 month follow up, 3 month follow up

    Caregiver sleep diary variables include sleep onset latency (lights-out until sleep onset), wake after sleep onset, total sleep time, and sleep efficiency (total sleep time/time in bed x 100%). Caregivers wear actigraphs (Fitbit Inspire 3, Google), a watch-like device that monitors light and gross motor activity. Data analyzed using 30s epochs. Validated algorithm estimates SOL, TST, WASO, sleep efficiency and other variables provided by diaries. A combination of diary and actigraphy data estimates bed/waketime variability. Caregivers wear devices 24/7 during each 1-week assessment.

  11. Electronic Sleep Diaries - Caregiver

    Time frame: baseline, within 1 week post treatment, 1 month follow up, 3 month follow up

    Caregiver sleep diary variables include sleep onset latency (lights-out until sleep onset), wake after sleep onset, total sleep time, and sleep efficiency (total sleep time/time in bed x 100%). Caregiver will complete electronic diaries each morning (~5 mins) during each 1-week assessment and throughout treatment.

  12. State-Trait Anxiety Inventory (STAI-Y1) - Caregiver

    Time frame: baseline, within 1 week post treatment, 1 month follow up, 3 month follow up

    State-Trait Anxiety Inventory (STAI-Y1) includes 20 self-descriptive statements rated according to how the caregiver generally feels on a 4-point scale [1 (not at all) to 4 (very much so)]. Scores range from 20-80 with higher scores indicate greater levels of anxiety.

  13. Beck Depression Inventory -II - Caregiver

    Time frame: baseline, within 1 week post treatment, 1 month follow up, 3 month follow up

    Beck Depression Inventory (BDI-II) includes 21 items that measures the severity of depressive symptomatology on a 4-point scale (0-absence of symptoms; 3-severe). Scores range from 0-63 with higher scores indicating higher severity of depressive symptoms.

  14. Fatigue Severity Scale - Caregiver

    Time frame: baseline, within 1 week post treatment, 1 month follow up, 3 month follow up

    Fatigue Severity Scale includes 9 items on severity of fatigue and how fatigue interferes with activities on a 7-point scale (1-strongly disagree; 7-strongly agree). Scores range from 9-63 with higher scores indicating severe fatigue symptoms.

  15. Daily Fatigue - Caregiver

    Time frame: baseline, within 1 week post treatment, 1 month follow up, 3 month follow up

    Daily Fatigue rated on electronic diaries (0-none;100-most intense imaginable)

  16. Caregiver Strain Index - Caregiver

    Time frame: baseline, within 1 week post treatment, 1 month follow up, 3 month follow up

    Caregiver Strain Index (CSI) includes 12 items on caregiving impact on well-being. Scoring range 0-26 with higher scores indicate greater caregiver strain

Other outcomes

  1. Pubertal Development Scale (PDS)

    Time frame: baseline, within 1 week post treatment, 1 month follow up, 3 month follow up

    Self-report questionnaire used to assess pubertal status

Study contacts

Contact information is provided by the study sponsor or research team.

Christina S McCrae, PhD

CONTACT

[email protected]

813-974-1804

Sponsors and collaborators

Lead sponsor

University of South Florida

Other

Registry information

Acronym: NiteCAPP JR

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Jul 29, 2025
Registry last updated
Jun 15, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.